TPST — Tempest Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $45.02m
- $30.74m
Annual cashflow statement for Tempest Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -36.4 | -28.3 | -35.7 | -29.5 | -41.8 |
| Depreciation | |||||
| Non-Cash Items | 5.52 | 2.68 | 2.88 | 4.45 | 6.76 |
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.296 | -0.705 | 1.12 | -2.69 | 1.67 |
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Cash from Operating Activities | -30.4 | -26 | -31.1 | -27.4 | -33 |
| Capital Expenditures | -0.026 | -0.135 | -0.562 | -0.17 | -0.435 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 0 | 0.038 | 0 | — | — |
| Sale/Maturity of Investment | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -0.026 | -0.097 | -0.562 | -0.17 | -0.435 |
| Financing Cash Flow Items | — | 10.5 | 0 | — | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 5.39 | 59.1 | 11.4 | 35.6 | 24.5 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -24.9 | 33 | -20.2 | 8.07 | -8.96 |